Zetomipzomib

DB16070InvestigationalSmall molecule

Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).

Formula / weight: C₃₀H₄₂N₄O₈ · 586.686 g/mol (avg)
Also known as: (2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide
Code names: KZR-616

Resolves to

Compound

UNIIO4BT6C02M2CAS1629677-75-3ChEMBLCHEMBL4297468

Structure

InChIKeyGHYOCDFICYLMRF-UTIIJYGPSA-NSMILESCOC1=CC=C(C=C1)[C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CCCC1)C(=O)[C@@]1(C)CO1

What you can answer from here — as of September 12, 2026

5Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of Zetomipzomib, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account